Clinical trial for improving liver function

Clinical trial for improving liver function - ILF trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004269

Enrollment

Registered

2010-10-01

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic liver disease with hypersplenism

Interventions

Splenectomy Irradiation of spleen

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic liver disease Thrombocytopenia (=< 100 / mL) which makes patients difficult to be treated with interferon or anti-HCC Therapy. PS = 0 or 1 Life expectancy of at least 6 months Written informed consent was obtained

Exclusion criteria

Exclusion criteria: Presence of esophageal or gastric varix at risk of bleeding within 6 months Patients with HCC who need to be treated within 6 months Pregnant or nursing patients Presence of lung fibrosis Patients who associated with heavy cardiac or renal disease Patients diagnosed to be inappropriate by an attending doctor

Design outcomes

Primary

Measure	Time frame
Symptom of hypersplenism Liver functional reserve	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026